Frode Krøll
11 Papers
28 Citations
Frode Krøll is an academic researcher. The author has contributed to research in topics: Psoriatic arthritis & Rheumatoid arthritis. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study
Brigitte Michelsen,Eirik Kristianslund,Joseph Sexton,Hilde Berner Hammer,Karen Minde Fagerli,Elisabeth Lie,Ada Wierød,Synøve Kalstad,Erik Rødevand,Frode Krøll,Glenn Haugeberg,Tore K Kvien +11 more
TL;DR: Depression and anxiety may reduce likelihood of joint remission based on composite scores in rheumatoid arthritis and PsA and should be taken into account in individual patients when making a shared decision on a treatment target.
208
Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.
Brigitte Michelsen,Till Uhlig,Joseph Sexton,Désirée van der Heijde,Hilde Berner Hammer,Eirik Kristianslund,Ada Wierød,Gunnstein Bakland,Erik Rødevand,Frode Krøll,Jon Håvard Loge,Glenn Haugeberg,Tore K Kvien +12 more
TL;DR: Health-related quality of life was overall similar in patients with RA and patients with psoriatic arthritis—with a tendency to worse scores in PsA—and worse compared with Norwegian general population controls.
Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Till Uhlig,Elisabeth Lie,Vibeke Norvang,Åse Stavland Lexberg,Erik Rødevand,Frode Krøll,Synøve Kalstad,Inge C. Olsen,Tore K Kvien +8 more
TL;DR: In daily clinical practice, the DAS28 and RAPID3 definitions identified remission about twice as often as the ACR/EULAR Boolean, SDAI, and CDAI.
27
Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
Brigitte Michelsen,Joseph Sexton,Ada Wierød,Gunnstein Bakland,Erik Rødevand,Frode Krøll,Tore K Kvien +6 more
TL;DR: Golimumab drug survival was not significantly different between bDMARD naïve and non-naïve RA, PsA and ax-SpA patients, nor between RA and PsA patients treated with vs. without concomitant csDMARDs.
17
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.
Vibeke Norvang,Joseph Sexton,Eirik Kristianslund,Inge C. Olsen,Till Uhlig,Gunnstein Bakland,Frode Krøll,Erik Rødevand,Ada Wierød,Tore K Kvien,Josef S Smolen,Daniel Aletaha,Espen A Haavardsholm +12 more
TL;DR: Levels of 3-month disease activity improvement can inform clinicians when deciding to continue or adjust ongoing therapy in a treat-to-target strategy aiming for remission or low disease activity within 6 months.
13